These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 16680544)

  • 41. The effect of atrial pacing therapies on atrial tachyarrhythmia burden and frequency: results of a randomized trial in patients with bradycardia and atrial tachyarrhythmias.
    Lee MA; Weachter R; Pollak S; Kremers MS; Naik AM; Silverman R; Tuzi J; Wang W; Johnson LJ; Euler DE;
    J Am Coll Cardiol; 2003 Jun; 41(11):1926-32. PubMed ID: 12798559
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of continuous versus intermittent monitoring of atrial arrhythmias.
    Ziegler PD; Koehler JL; Mehra R
    Heart Rhythm; 2006 Dec; 3(12):1445-52. PubMed ID: 17161787
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical characteristics and outcome of lone atrial fibrillation at a tertiary referral centre: the Groote Schuur Hospital experience.
    Thomas V; Schulein S; Millar RN; Mayosi BM
    Cardiovasc J Afr; 2018; 29(5):268-272. PubMed ID: 30395140
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High atrial antitachycardia pacing therapy efficacy is associated with a reduction in atrial tachyarrhythmia burden in a subset of patients with sinus node dysfunction and paroxysmal atrial fibrillation.
    Gillis AM; Koehler J; Morck M; Mehra R; Hettrick DA
    Heart Rhythm; 2005 Aug; 2(8):791-6. PubMed ID: 16051111
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship between device-detected burden and duration of atrial fibrillation and risk of ischemic stroke.
    Al-Gibbawi M; Ayinde HO; Bhatia NK; El-Chami MF; Westerman SB; Leon AR; Shah AD; Patel AM; De Lurgio DB; Tompkins CM; Lloyd MS; Merchant FM; Kiani S
    Heart Rhythm; 2021 Mar; 18(3):338-346. PubMed ID: 33250442
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of high-grade atrioventricular block and cumulative frequent pacing on atrial arrhythmias.
    Wali E; Deshmukh A; Bukari A; Broman M; Aziz Z; Beaser A; Upadhyay G; Nayak HM; Tung R; Ozcan C
    Pacing Clin Electrophysiol; 2018 Sep; 41(9):1158-1164. PubMed ID: 29931776
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency department.
    Stiell IG; Macle L;
    Can J Cardiol; 2011; 27(1):38-46. PubMed ID: 21329861
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ventricular high-rate episodes in pacemaker diagnostics identify a high-risk subgroup of patients with tachy-brady syndrome.
    Willems R; Morck ML; Exner DV; Rose SM; Gillis AM
    Heart Rhythm; 2004 Oct; 1(4):414-21. PubMed ID: 15851193
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DDIR versus VVIR pacing in patients with paroxysmal atrial tachyarrhythmias.
    Vanerio G; Maloney JD; Pinski SL; Simmons TW; Castle LW; Trohman RG; Wilkoff BL
    Pacing Clin Electrophysiol; 1991 Nov; 14(11 Pt 1):1630-8. PubMed ID: 1721153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Baseline characteristics and management of patients with atrial fibrillation/flutter in the emergency department: results of a prospective, multicentre registry in China.
    Zhang H; Yang Y; Zhu J; Shao X; Liu Y; Zhao L; Yu P; Zhang H; He Q; Gu X
    Intern Med J; 2014 Aug; 44(8):742-8. PubMed ID: 24893684
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A controlled study on the effect of verapamil on atrial tachycaarrhythmias in patients with brady-tachy syndrome implanted with a DDDR pacemaker.
    Boriani G; Bertaglia E; Carboni A; Latini R; Biffi M; Martignani C; Sciotto F; Branzi A
    Int J Cardiol; 2005 Sep; 104(1):73-6. PubMed ID: 16137513
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Silent ischaemic brain lesions related to atrial high rate episodes in patients with cardiac implantable electronic devices.
    Benezet-Mazuecos J; Rubio JM; Cortés M; Iglesias JA; Calle S; de la Vieja JJ; Quiñones MA; Sanchez-Borque P; de la Cruz E; Espejo A; Farré J
    Europace; 2015 Mar; 17(3):364-9. PubMed ID: 25336664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incidence of newly detected atrial arrhythmias via implantable devices in patients with a history of thromboembolic events.
    Ziegler PD; Glotzer TV; Daoud EG; Wyse DG; Singer DE; Ezekowitz MD; Koehler JL; Hilker CE
    Stroke; 2010 Feb; 41(2):256-60. PubMed ID: 20044517
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incidence of ischemic stroke or transient ischemic attack in patients with multiple risk factors with or without atrial fibrillation: a retrospective cohort study.
    Yuan Z; Makadia R; Ryan P; Yannicelli D; Nessel C; Sarich T
    Curr Med Res Opin; 2015; 31(7):1257-66. PubMed ID: 25877807
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The importance of atrial fibrillation/flutter as a cause of ischemic stroke.
    Haft JI
    Int J Cardiol; 2012 Jun; 158(1):143-4. PubMed ID: 22560939
    [No Abstract]   [Full Text] [Related]  

  • 56. Pacemaker-detected atrial fibrillation burden and risk of ischemic stroke or thromboembolic events-A cohort study.
    Chu SY; Jiang J; Wang YL; Sheng QH; Zhou J; Ding YS
    Heart Lung; 2020; 49(1):66-72. PubMed ID: 31376922
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation.
    Black-Maier E; Kim S; Steinberg BA; Fonarow GC; Freeman JV; Kowey PR; Ansell J; Gersh BJ; Mahaffey KW; Naccarelli G; Hylek EM; Go AS; Peterson ED; Piccini JP;
    Clin Cardiol; 2017 Sep; 40(9):746-751. PubMed ID: 28543401
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rationale and design of a randomized clinical trial to assess the role of overdrive and triggered prevention pacing therapies in reducing atrial fibrillation: the Study of Atrial Fibrillation Reduction (SAFARI).
    Gold MR; Hoffmann E;
    Am Heart J; 2006 Aug; 152(2):231-6. PubMed ID: 16875902
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Higher Risk of Ischemic Events in Secondary Prevention for Patients With Persistent Than Those With Paroxysmal Atrial Fibrillation.
    Koga M; Yoshimura S; Hasegawa Y; Shibuya S; Ito Y; Matsuoka H; Takamatsu K; Nishiyama K; Todo K; Kimura K; Furui E; Terasaki T; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Kameda T; Nagakane Y; Yagita Y; Kario K; Shiozawa M; Sato S; Yamagami H; Arihiro S; Toyoda K;
    Stroke; 2016 Oct; 47(10):2582-8. PubMed ID: 27531346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.